Silence Therapeutics plc financial data

Symbol
SLN on Nasdaq, SLNCF on OTC
Location
72 Hammersmith Road, London, United Kingdom
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 937 %
Debt-to-equity 68.7 %
Return On Equity -62.2 %
Return On Assets -36.9 %
Operating Margin -321 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142M shares
Common Stock, Shares, Outstanding 142M shares
Entity Public Float 738M USD
Common Stock, Value, Issued 10.3M USD
Weighted Average Number of Shares Outstanding, Basic 142M shares +0.36%
Weighted Average Number of Shares Outstanding, Diluted 142M shares +0.36%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 25.8M USD -89.4%
Research and Development Expense 81.1M USD +1.91%
General and Administrative Expense 24.2M USD -24.7%
Operating Income (Loss) -83M USD +12.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -64.2M USD +41%
Income Tax Expense (Benefit) 335K USD -98%
Net Income (Loss) Attributable to Parent -64.5M USD +41%
Earnings Per Share, Basic 0 USD/shares +40%
Earnings Per Share, Diluted 0 USD/shares +40%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 82M USD
Cash, Cash Equivalents, and Short-term Investments 102M USD
Accounts Receivable, after Allowance for Credit Loss, Current 28K USD
Other Assets, Current 9.26M USD
Assets, Current 134M USD
Property, Plant and Equipment, Net 1.66M USD
Operating Lease, Right-of-Use Asset 192K USD
Goodwill 10.6M USD +13%
Other Assets, Noncurrent 399K USD
Assets 147M USD
Contract with Customer, Liability, Current 301K USD
Liabilities, Current 17.4M USD
Contract with Customer, Liability, Noncurrent 55.3M USD
Operating Lease, Liability, Noncurrent 97K USD
Liabilities 72.7M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.07M USD
Retained Earnings (Accumulated Deficit) -551M USD
Stockholders' Equity Attributable to Parent 74.1M USD -41.5%
Liabilities and Equity 147M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.3M USD -34.6%
Net Cash Provided by (Used in) Financing Activities 133M USD
Net Cash Provided by (Used in) Investing Activities -44.4M USD +11.1%
Common Stock, Shares, Issued 142M shares
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares
Deferred Tax Assets, Valuation Allowance 61.4M USD -3.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.19 pure
Deferred Tax Assets, Gross 61.4M USD -3.6%
Operating Lease, Liability 117K USD
Depreciation 73K USD -17%
Payments to Acquire Property, Plant, and Equipment 4K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.7M USD +18.8%
Lessee, Operating Lease, Liability, to be Paid 117K USD
Property, Plant and Equipment, Gross 6.34M USD -1.45%
Operating Lease, Liability, Current 85K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 117K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD